Just hours after Haryana Health Minister Anil Vij, who was administered a dose of Covaxin last month, confirmed he has developed Coronavirus symptoms, the Union Health Ministry on Saturday clarified that Vij took only the first dose of the two-dose vaccine.
"The antibodies against the infection build up in a human being only after a specific number of days pass after the second dose of the vaccine is taken. Since, this is a two-dose vaccine. Minister in question has taken only one dose of the vaccine," the ministry said in a statement.
In the case of this vaccine, trial volunteers receive two intramuscular injections approximately 28 days apart.
Participants are randomly assigned to receive Covaxin or placebo. The trial is double-blinded, such that the investigators, the participants and the company are not aware of who is assigned to which group.
The statement from the ministry came after the 67-year-old minister tested positive two weeks after being given a shot of the vaccine, which is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research, at a hospital in Ambala as part of the third phase of the trial.
"I have been tested Corona positive. I am admitted in Civil Hospital Ambala Cantt. All those who have come in close contact to me are advised to get themselves tested for corona," Vij tweeted on Saturday.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU